• Luuk Montoya posted an update 6 days, 16 hours ago

    Clinicians must be aware of the methodology used and adjust target levels accordingly to avoid Lapatinib potential effects on efficacy and toxicity. “”Alba AC, Verocai Flaman F, Granton J, Delgado DH. Patent foramen ovale does not have a negative impact on early outcomes in patients undergoing liver transplantation. Clin Transplant 2011: 25: 151�C155. ? 2010 John Wiley & Sons A/S. Abstract:? Objective:? To identify the impact of the presence of patent foramen ovale (PFO) in patients undergoing liver transplantation. Methods:? Twenty-seven pre-liver transplant patients who had a PFO (PFO group) were identified and compared with 61 patients without PFO (NoPFO group). Patients were matched according to age, gender and cause of liver disease. The diagnosis of PFO was made by transthoracic echocardiography prior to liver transplantation. Patient baseline characteristics and complications during the early post-transplant period were analyzed. Results:? The mean age in the PFO group was 47?��?14 (range 18�C68) yr and 50?��?11 (range 12�C65) yr in the NoPFO group. The PFO group had a mean model for end-stage liver disease (MELD) score of 15?��?10 whereas in the NoPFO group the MELD score was 19?��?10 (p?=?0.08). There were non-significant differences in echocardiographic parameters between groups. Duration of mechanical ventilation and the incidence of neurological complications were similar. Thirty-day mortality rate was similar in both groups; only one patient in the NoPFO group died within the first 30?days post-transplantation. Conclusions:? The presence of PFO in patients with end-stage liver disease undergoing liver transplantation does not appear to affect patient outcomes during the peri-operative period. “”Immune function test (Immuknow?) is a measure of cell-mediated immunity based on peripheral CD4+?T cell adenosine triphosphate activity (desired range, 225�C525?ng/mL). We evaluated the role of immune function test (IFT) in monitoring and adjustment of immunosuppression in orthotopic liver transplant (OLT) recipients. A total of 289 IFTs were obtained from 171 patients from March 2007 to June 2008. Graft/patient status was classified as stable, serious infection, or malignancy. IFT levels were analyzed with duration of follow-up after OLT, graft/patient status, and the presence of hepatitis C (HCV) infection. The mean age was 54?��?14?yr, with 62% men. The median follow-up was 65 (2�C249) months. Mean IFT levels were significantly lower in patients who were <24?months than in those ��24?months post-OLT (220?��?19.5 vs. 257?��?11.3?ng/mL, p?=?0.03). Clinically stable patients had higher IFT levels than those with serious infection or malignancy (254?��?11.1 vs. 162.5?��?23.9, p?<?0.001). HCV-infected patients had lower IFT levels than uninfected patients (206.7?��?15.7 vs. 273?��?12.0?ng/mL, p?<?0.001).